Compare Amgen, Inc. (AMGN) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while GraniteShares 2x Long COIN Daily ETF trades at $4.2. The key difference: Amgen, Inc. pays a 2.43% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | CONL | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $417.20 | $48.70 |
52-Week Low | $271.18 | $3.93 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.38, up 11.45% in the past 24 hours but remains significantly below year-to-date levels with a 67% decline. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF tracks Coinbase stock with 2x daily leverage, exposing investors to amplified volatility from cryptocurrency market movements.
The outlook remains challenging due to the volatility decay inherent in daily-reset leveraged products. While recent cryptocurrency strength provides potential upside, the structural design of CONL creates significant long-term erosion risk. Investors should understand the product's mechanics before considering positions in this high-risk instrument.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →
